Zacks: Analysts Expect Evoke Pharma, Inc. (EVOK) to Announce -$0.16 EPS
Wall Street brokerages forecast that Evoke Pharma, Inc. (NASDAQ:EVOK) will post earnings per share of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Evoke Pharma’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.19). Evoke Pharma reported earnings per share of ($0.24) in the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The company is expected to announce its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.74). For the next year, analysts expect that the business will post earnings of $0.05 per share, with EPS estimates ranging from ($0.52) to $1.16. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.15). During the same quarter in the previous year, the firm posted ($0.41) EPS.
Evoke Pharma (NASDAQ:EVOK) opened at 3.88 on Thursday. The stock’s market capitalization is $59.71 million. The stock’s 50 day moving average is $3.14 and its 200-day moving average is $2.74. Evoke Pharma has a 52-week low of $1.35 and a 52-week high of $4.55.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/12/zacks-analysts-expect-evoke-pharma-inc-evok-to-announce-0-16-eps.html.
A hedge fund recently raised its stake in Evoke Pharma stock. Vanguard Group Inc. grew its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 15.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 523,650 shares of the specialty pharmaceutical company’s stock after buying an additional 68,544 shares during the period. Vanguard Group Inc. owned approximately 3.40% of Evoke Pharma worth $1,341,000 as of its most recent filing with the Securities & Exchange Commission. 12.88% of the stock is owned by institutional investors.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.